Cargando…
Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study
INTRODUCTION: We evaluated the safety of current treatment regimens for patients with RA and HBV in a large US cohort. METHODS: We identified biologic and nonbiologic treatment episodes of RA patients using 1997 to 2011 national data from the US Veterans Health Administration. Eligible episodes had...
Autores principales: | Burton, Mary Jane, Curtis, Jeffrey R, Yang, Shuo, Chen, Lang, Singh, Jasvinder A, Mikuls, Ted R, Winthrop, Kevin L, Baddley, John W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4489034/ https://www.ncbi.nlm.nih.gov/pubmed/26001631 http://dx.doi.org/10.1186/s13075-015-0628-z |
Ejemplares similares
-
Risk of Serious Infection in Patients With Rheumatoid Arthritis Treated With Biologic Versus Nonbiologic Disease‐Modifying Antirheumatic Drugs
por: Ozen, Gulsen, et al.
Publicado: (2019) -
Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs
por: Mori, Shunsuke
Publicado: (2011) -
Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs
por: Zhang, Huabin F, et al.
Publicado: (2014) -
Sarilumab and Nonbiologic Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
por: Fleischmann, Roy, et al.
Publicado: (2017) -
Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration
por: Navarro-Millán, Iris, et al.
Publicado: (2016)